Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M E Armstrong

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Gerontology|June 16, 2001
Age-related alterations in basal expression and in vitro, tumour necrosis factor alpha mediated, upregulation of CD11bM E Armstrong, H D Alexander, J L Ritchie, et al.
Virology|April 1, 1987
Identification of an Epstein-Barr virus glycoprotein which is antigenically homologous to the varicella-zoster virus glycoprotein II and the herpes simplex virus glycoprotein BE A Emini, J Luka, M E Armstrong, et al.
Journal of Medical Virology|April 1, 1986
Establishment and characterization of a chronic infectious mononucleosislike syndrome in common marmosetsE A Emini, J Luka, M E Armstrong, et al.
Antimicrobial Agents and Chemotherapy|December 1, 1994
Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compoundsJ Tomassini, H Selnick, M E Davies, et al.
Vaccine|January 1, 1993
Single and booster dose responses to an inactivated hepatitis A virus vaccine: comparison with immune serum globulin prophylaxisD Shouval, Y Ashur, R Adler, et al.
QJM : Monthly Journal of the Association of Physicians|August 2, 2013
Sarcoidosis, alveolar β-actin and pulmonary fibrosisG Cooke, P Govender, C J Watson, et al.
Journal of Hepatology|January 1, 1993
Development of the formalin-inactivated hepatitis A vaccine, VAQTA from the live attenuated virus strain CR326FM E Armstrong, P A Giesa, J P Davide, et al.
Vaccine|January 1, 1992
Safety profile and immunogenicity of an inactivated vaccine derived from an attenuated strain of hepatitis AE F Ellerbeck, J A Lewis, D Nalin, et al.
Virology|October 1, 1988
Antigenic analysis of the Epstein-Barr virus major membrane antigen (gp350/220) expressed in yeast and mammalian cells: implications for the development of a subunit vaccineE A Emini, W A Schleif, M E Armstrong, et al.
QJM : Monthly Journal of the Association of Physicians|December 14, 2017
Toll-like receptor 3 L412F polymorphism promotes a persistent clinical phenotype in pulmonary sarcoidosisG Cooke, I Kamal, M Strengert, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Gerontology|June 16, 2001
Age-related alterations in basal expression and in vitro, tumour necrosis factor alpha mediated, upregulation of CD11bM E Armstrong, H D Alexander, J L Ritchie, et al.
Virology|April 1, 1987
Identification of an Epstein-Barr virus glycoprotein which is antigenically homologous to the varicella-zoster virus glycoprotein II and the herpes simplex virus glycoprotein BE A Emini, J Luka, M E Armstrong, et al.
Journal of Medical Virology|April 1, 1986
Establishment and characterization of a chronic infectious mononucleosislike syndrome in common marmosetsE A Emini, J Luka, M E Armstrong, et al.
Antimicrobial Agents and Chemotherapy|December 1, 1994
Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compoundsJ Tomassini, H Selnick, M E Davies, et al.
Vaccine|January 1, 1993
Single and booster dose responses to an inactivated hepatitis A virus vaccine: comparison with immune serum globulin prophylaxisD Shouval, Y Ashur, R Adler, et al.
QJM : Monthly Journal of the Association of Physicians|August 2, 2013
Sarcoidosis, alveolar β-actin and pulmonary fibrosisG Cooke, P Govender, C J Watson, et al.
Journal of Hepatology|January 1, 1993
Development of the formalin-inactivated hepatitis A vaccine, VAQTA from the live attenuated virus strain CR326FM E Armstrong, P A Giesa, J P Davide, et al.
Vaccine|January 1, 1992
Safety profile and immunogenicity of an inactivated vaccine derived from an attenuated strain of hepatitis AE F Ellerbeck, J A Lewis, D Nalin, et al.
Virology|October 1, 1988
Antigenic analysis of the Epstein-Barr virus major membrane antigen (gp350/220) expressed in yeast and mammalian cells: implications for the development of a subunit vaccineE A Emini, W A Schleif, M E Armstrong, et al.
QJM : Monthly Journal of the Association of Physicians|December 14, 2017
Toll-like receptor 3 L412F polymorphism promotes a persistent clinical phenotype in pulmonary sarcoidosisG Cooke, I Kamal, M Strengert, et al.
Pageof 3